ROSSI, COSMO
 Distribuzione geografica
Continente #
NA - Nord America 521
EU - Europa 474
AS - Asia 199
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1196
Nazione #
US - Stati Uniti d'America 520
IT - Italia 161
CN - Cina 109
SE - Svezia 76
TR - Turchia 54
UA - Ucraina 54
GB - Regno Unito 53
IE - Irlanda 40
FR - Francia 36
DE - Germania 29
IN - India 21
BE - Belgio 13
VN - Vietnam 13
FI - Finlandia 9
NL - Olanda 2
AU - Australia 1
CA - Canada 1
EU - Europa 1
IR - Iran 1
JP - Giappone 1
RO - Romania 1
Totale 1196
Città #
Chandler 171
Jacksonville 86
Ann Arbor 67
Chieti 46
Princeton 43
Dublin 40
Dearborn 38
Southend 38
Nanjing 31
Izmir 26
Altamura 18
Nanchang 15
Beijing 14
Brussels 13
Cambridge 13
Dong Ket 13
Wilmington 11
Jinan 8
Woodbridge 8
Boardman 7
Collecorvino 7
Tianjin 6
Finale Ligure 5
Norwalk 5
Kunming 4
Milan 4
Shenyang 4
Changsha 3
Hebei 3
Munich 3
Rome 3
Augusta 2
Carini 2
Cattolica 2
Cepagatti 2
Grafing 2
Hangzhou 2
Jiaxing 2
L'aquila 2
Orsogna 2
Redwood City 2
Sheffield 2
Shenzhen 2
Siracusa 2
Zhengzhou 2
Ardabil 1
Ardea 1
Bari 1
Borca 1
Busso 1
Castellamonte 1
Changchun 1
Chaoyang 1
Chengdu 1
Civitella Del Tronto 1
Clearwater 1
Collegno 1
Frankfurt am Main 1
Frascati 1
Fuzhou 1
Gavirate 1
Guangzhou 1
Hefei 1
Helsinki 1
Houston 1
Jülich 1
Lanzhou 1
Laurel 1
Los Angeles 1
Mcallen 1
Mergo 1
Messina 1
Napoli 1
Ningbo 1
Redmond 1
Sansepolcro 1
Shizuoka 1
Silvi 1
Taizhou 1
Teramo 1
Termoli 1
Toronto 1
Tyresö 1
Vasto 1
Vittuone 1
Totale 821
Nome #
Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib 146
A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer 125
Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice 95
Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. 94
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 81
null 77
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 70
Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression 68
Prognostic relevance of LGALS3BP in human colorectal carcinoma 66
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 64
Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells 64
Morphological and metabolic changes in the nigro-striatal pathway of Synthetic Proteasome Inhibitor (PSI)-treated rats: an MRI and MRS study. 62
A developmental model of paragangliar tumorigenesis highlights therapeutic targets 62
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 61
MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells 52
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 50
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 35
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 32
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 25
POSTER SESSIONS 25
Resveratrol has anti-thyroid effects both in vitro and in vivo 17
null 11
Intragastric administration of the monomeric allergoid Par-j1 induces up-regulation of CD4 1 CD25 1 IL-10 1 T regulatory cells (Tregs) in spleen and mesenteric lymph node in sensitized BALB/c mice: 691 6
Totale 1388
Categoria #
all - tutte 2407
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2407


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201848 0000 00 03 127197
2018/2019150 8464 395 1610 72742
2019/2020318 581444 3529 4723 1856237
2020/2021211 213228 1430 1810 21251326
2021/2022168 56642 611 1113 961439
2022/2023341 38783466 3172 220 0000
Totale 1388